No. Levamisole has no documented effect on body weight or metabolism, and using it for weight loss would be unsupported and potentially unsafe.
A fever may be an early sign of agranulocytosis. Contact a healthcare professional immediately; a complete blood count will likely be required.
Brand-name tablets may have a distinctive imprint or color designated by the manufacturer, while generic versions often display a different imprint. Both contain the same 50 mg of Levamisole.
Levamisole is not typically screened for in routine workplace drug testing panels, which focus on substances of abuse. However, specialized testing could detect it if specifically requested.
Yes, provided you carry the prescription label and the medication is in its original packaging. Check the destination country’s regulations regarding import of prescription drugs.
Crushing may alter the drug’s absorption profile. Consult a pharmacist before modifying the tablet; an alternative liquid formulation may be available.
Both are antiparasitic agents, but albendazole is currently preferred in the UK due to a more favorable safety profile and broader efficacy. Levamisole is reserved for cases where other agents are unsuitable.
Levamisole does not have a direct impact on glucose metabolism, but severe infection or systemic illness could indirectly influence blood sugar control.
The primary reasons include development of severe side effects such as agranulocytosis, hypersensitivity reactions, or patient intolerance due to gastrointestinal upset.
Dicaris is a brand-name medication that contains Levamisole as its active component. Levamisole belongs to the antiparasitic class of drugs and is supplied in a pill form, each tablet containing 50 mg of the active ingredient. In the United Kingdom, Dicaris is a prescription-only product and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). While Levamisole was formerly approved for the treatment of certain intestinal worm infections, its use in human medicine has become limited owing to safety concerns. The medication may still be prescribed in specific clinical circumstances under specialist supervision.
Levamisole exerts its antiparasitic effect by acting as an agonist at nicotinic acetylcholine receptors on the neuromuscular junctions of nematodes (roundworms). Stimulation of these receptors leads to sustained muscle contraction, paralysis, and eventual expulsion of the parasite from the gastrointestinal tract.
In addition to its direct antiparasitic activity, Levamisole has been observed to modulate the immune system. It can enhance cell-mediated immunity by stimulating the activity of macrophages and natural killer cells, and by augmenting the production of certain cytokines. These immunomodulatory actions have prompted investigation of Levamisole in several off-label therapeutic areas, although robust evidence supporting routine clinical use outside antiparasitic treatment is lacking.
The onset of antiparasitic action typically occurs within a few hours after ingestion, with peak plasma concentrations reached within 2-4 hours. Levamisole is moderately bioavailable when taken orally and is partially metabolised in the liver before renal excretion.
Intestinal helminth infections: Historically, Levamisole has been used to treat infections caused by Ascaris lumbricoides (roundworm) and Ancylostoma duodenale (hookworm). In the UK, it is no longer a first-line agent and is generally reserved for cases where alternative therapies are unsuitable.
Adjunctive immunotherapy (off-label): Limited clinical investigations have examined Levamisole as an adjunct in colorectal cancer and certain autoimmune conditions. Such uses remain experimental and are not approved by the MHRA.
Because contemporary clinical guidelines in the UK favor other anthelmintics (e.g., albendazole, mebendazole), Dicaris is prescribed only when specific clinical judgement deems it appropriate.
Colorectal cancer adjuvant therapy: Small randomized trials have explored Levamisole combined with 5-fluorouracil, suggesting modest improvements in disease-free survival. However, these studies are dated, and newer chemotherapeutic regimens have superseded this combination. Levamisole’s use for this indication is not approved and should be considered only within a clinical trial or specialist setting.
Rheumatoid arthritis: Early studies indicated potential benefits of Levamisole as an immunomodulator, but subsequent research failed to demonstrate consistent efficacy, and safety concerns curtailed its adoption.
Disclaimer: Off-label use of Levamisole requires careful medical supervision, individualized risk assessment, and should be undertaken only when clinically justified.
General Advice: Always inform your healthcare provider of all medications, supplements, and herbal products you are taking before starting Dicaris.
This article provides educational information about Dicaris and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
